Onco Actu du 31 octobre 2018

	1. Biologie
Patient-derived Paediatric Brain Tumour Models [ESMO] Patient-derived orthotopic xenograft models described in this study, as well as additional lines being developed and characterised, are catalogued online and shared with other researchers at the Brain Tumor Resource Laboratory.
	4.2 Dép., diag. & prono. - Génome
Long read technologies – the next frontier of clinical genome sequencing? [PHG Foundation] The opportunities which LRS does present are currently evident for cancer, rare disease and infectious disease. It will be important to keep a close watch on LRS technologies as they continue to evolve rapidly.
	4.3 Dép., diag. & prono. - Industriels
Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling [Illumina] The newest addition to the Illumina oncology portfolio offers researchers the ability to measure Tumor Mutational Burden and Microsatellite Instability, and detect other known and emerging biomarkers.
	5.10 Traitements - Essais
Research integrity: clinical trials transparency [House of Commons Science and Technology Committee] A range of UK and EU rules and guidelines are now in force to improve clinical trials transparency, in terms of tackling non-registration, non-reporting and mis-reporting. However, despite these rules, around half of clinical trials are currently left unreported, clinical trial registration is not yet universal in the UK, and reported outcomes do not always align with the original study proposal.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
New Penn Medicine Center Brings Immunotherapy Research to Brain Tumor Treatment [Penn Medicine] The team will investigate new immune therapies for glioblastoma and, in particular, design and test new CAR T cell therapies.
City Of Hope Opens First-Of-Its-Kind Car T Clinical Trial For Patients With Her2-Positive Breast Cancer That Has Spread To The Brain [City of Hope] The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
	5.12.6 Immunothérapies - AMM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) [Merck] First Anti-PD-1 Approved for First-Line Treatment of Squamous NSCLC Regardless of PD-L1 Expression.
	5.2 Pharma
Sanofi joins Open Targets [Open Targets] The freely available Open Targets Platform (www.targetvalidation.org) makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. The platform features over 21,000 targets associated with more than 10,000 diseases and receives around 1000 unique visits each week.
	5.2.1 Pharma - Partenariats
Roche taps Halozyme’s drug delivery tech for up to $520M [FierceBiotech] The Enhanze technology uses the enzyme hyaluronidase to break down hyaluronan, a natural sugar chain that forms a gel in the subcutaneous layer. This allows for the subcutaneous injection of treatments that might otherwise require infusion.
	6. Lutte contre les cancers
Report Outlines Priorities to Improve the Lives of Cancer Survivors and Caregivers (ACS] The report says efforts are needed to accelerate progress in 3 priority areas: 1) implementing routine assessment of survivors’ needs and functioning and caregivers’ needs; 2) facilitating personalized, tailored, information and referrals from diagnosis onward for both survivors and caregivers, shifting services from point of care (in clinical settings) to point of need outside of the clinic wherever possible; and 3) disseminating and supporting the implementation of new care methods and interventions.
	6.1 Observation
Half of kidney cancer patients initially misdiagnosed [Pharmafile] The call comes after Theresa May announced a new strategy aimed at increasing the number of people whose cancer is diagnosed early, from 1-in-2 people to 3-in-4.
Patient Survey Results Autumn 2018 [Kidney Cancer UK] The survey, which is the UK’s only kidney cancer focused annual survey, received 270 patient responses, exposing some startling facts: almost half (48%) were diagnosed at the most life-threatening stages, 3 and 4, where the prognosis is much worse.
	6.12 Ethique
Wellcome Sanger director apologises for management failings [The Guardian] Independent investigation criticises closed culture with few women at senior level.
Result of independent investigation into whistleblowing allegations released [Wellcome Sanger Institute] Independent barrister's report concludes that no wrongdoing took place, but that Institute procedures could be improved.
Top genomics institute clears director of bullying and gender discrimination [Nature] In particular, the investigation cleared geneticist Mike Stratton — head of the institute— — of bullying and gender discrimination, said a statement released by the Sanger on 30 October.
	6.5 Médecines alternatives/complémentaires
National Survey Reveals Surprising Number of Americans Believe Alternative Therapies Can Cure Cancer [ASCO] Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology (ASCO)’s second annual National Cancer Opinion Survey.
	6.7.1 IA/bioinformatique
Google Touts Speed, Accuracy From Machine Learning in DeepVariant [Genome Web] According to the researchers, DeepVariant outperformed both the Broad Institute's Genome Analysis Toolkit on the NA12878 sample from the Illumina Platinum Genomes dataset and the standard whole-genome sequencing of 35 replicates of NA12878.
Why Jupyter is data scientists’ computational notebook of choice [Nature] An improved architecture and enthusiastic user base are driving uptake of the open-source web tool.